Taiko PharmaceuticalTAIKO PHARMACEUTICAL CO., LTD.4574東証プライム医薬品FY ending Dec 2025, consolidated, J-GAAP
Out of every ¥100 of sales, about ¥7 is left as operating profit. Revenue changed +1.7% from the prior year, operating profit -27.0%.
Net margin × asset turnover = ROA; ROA × financial leverage = ROE
Denominators: average assets and average equity. Derived from reported values; ROE is shown only for positive profit and equity.
| Period | Net margin | Asset turnover | ROA | Financial leverage | ROE |
|---|---|---|---|---|---|
| 2021 | — | —× | -42.6% | —× | — |
| 2022 | — | —× | -26.1% | —× | — |
| 2023 | — | —× | -25.6% | —× | — |
| 2024 | 14.3% | 0.48× | 6.9% | 1.93× | 13.3% |
| 2025 | 14.4% | 0.51× | 7.3% | 1.63× | 11.9% |
Financial leverage can raise ROE; a higher value alone does not describe a company's overall condition.
Annual trends in tangible-asset ratios and goodwill balance.
Ratios are derived from reported values. Goodwill is shown only when separately reported; it is not inferred from combined intangible assets. Definition
Track R&D investment and how long operating capital remains tied up before sales turn into cash.
R&D is shown only for years with machine-readable disclosure. Days are estimates using year-end receivables, inventory and payables divided by annual revenue or cost of sales; financial companies are excluded.
| Item | FY ending Dec 2021 | FY ending Dec 2022 | FY ending Dec 2023 | FY ending Dec 2024 | FY ending Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 11,299 | 5,040 | 6,120 | 6,292 | 6,397 |
| Cost of revenue | 7,973 | 3,961 | 3,543 | 2,626 | 2,916 |
| Gross profit | 3,325 | 1,078 | 2,577 | 3,666 | 3,481 |
| SG&A | 7,694 | 4,157 | 3,583 | 3,036 | 3,022 |
| Operating income | -4,947 | -3,079 | -1,005 | 629 | 459 |
| Pretax income | -8,887 | -4,869 | -3,563 | 565 | 958 |
| Income tax | 706 | 25 | 47 | -332 | 34 |
| Net income attributable to owners | -9,594 | -4,895 | -3,611 | 898 | 923 |
| Operating margin | -43.8% | -61.1% | -16.4% | 10.0% | 7.2% |
Year-end figures from filings. Unreported items are omitted. Interest-bearing debt excludes lease liabilities.
Each bar totals 100% of assets; other is the residual.
| Item | FY ending Dec 2021 | FY ending Dec 2022 | FY ending Dec 2023 | FY ending Dec 2024 | FY ending Dec 2025 |
|---|---|---|---|---|---|
| Cash and equivalents | ¥5.52B | ¥2.8B | ¥5.24B | ¥4.53B | ¥4.26B |
| Total assets | ¥22.5B | ¥15B | ¥13.2B | ¥12.9B | ¥12.3B |
| Net assets | ¥12.8B | ¥8.04B | ¥6.74B | ¥7.96B | ¥8.52B |
| Share capital | ¥1.2B | ¥1.2B | ¥2.27B | ¥10M | ¥10M |
| Trade receivables | ¥4.06B | ¥1.8B | ¥1.99B | ¥2.43B | — |
| Property, plant and equipment | ¥7.11B | ¥6.4B | ¥3.58B | ¥3.27B | ¥3.31B |
| Intangible assets excluding goodwill | ¥299M | ¥222M | ¥1M | ¥27M | ¥34M |
| Investment securities | ¥1.01B | ¥533M | ¥236M | ¥461M | ¥0 |
| Current assets | ¥13.8B | ¥7.56B | ¥9.11B | ¥8.76B | ¥8.43B |
| Current liabilities | ¥4.32B | ¥2.79B | ¥3.05B | ¥2.85B | ¥2.51B |
| Trade payables | ¥309M | ¥274M | ¥375M | ¥338M | — |
| Long-term borrowings | ¥3.76B | ¥2.72B | ¥2B | ¥792M | — |
| Total liabilities | ¥9.73B | ¥7B | ¥6.48B | ¥4.95B | ¥3.75B |
| Equity attributable to owners of parent | ¥12.6B | ¥7.73B | ¥6.28B | ¥7.26B | ¥8.2B |
| Retained earnings | ¥10.1B | ¥5.24B | ¥1.63B | ¥2.53B | ¥3.45B |
| Treasury stock | -¥388M | -¥348M | -¥300M | -¥273M | -¥237M |
EDINET (FSA Japan)
有価証券報告書－第80期(2025/01/01－2025/12/31)
EDINET (FSA Japan)
有価証券報告書－第79期(2024/01/01－2024/12/31)
EDINET (FSA Japan)
有価証券報告書－第78期(2023/01/01－2023/12/31)
EDINET (FSA Japan)
有価証券報告書－第77期(2022/01/01－2022/12/31)
EDINET (FSA Japan)
有価証券報告書－第76期(令和3年1月1日－令和3年12月31日)
EDINET (FSA Japan)
有価証券報告書－第75期(令和2年4月1日－令和2年12月31日)
Extracted from XBRL: 46 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.